D57.413
Sickle-cell thalassemia, unspecified, with cerebral vascular involvement
Clinical Classification Guidelines
Code Also
- , if applicable cerebral infarction (I63.-)
Medical Intelligence & Overview
Sickle-cell thalassemia with cerebral vascular involvement is a complex blood disorder that combines features of sickle-cell disease and thalassemia, leading to significant health challenges. This condition affects the shape and function of red blood cells and can result in complications such as stroke or other cerebrovascular problems. Understanding the nature of this disease can help patients and caregivers to be better informed about the risks and management options.
Causes & Symptoms
Clinical Causes: Inherited genetic mutations that affect hemoglobin production, leading to abnormal red blood cell shapes and functions. A combination of gene variations associated with sickle-cell disease and thalassemia, passed from parents to offspring. Genetic inheritance patterns that increase the chance of developing both sickle-cell disease and thalassemia traits or disease. Environmental factors generally do not directly cause this blood disorder but can influence disease severity.
Key Symptoms: Episodes of pain, often called sickle-cell crises, due to blocked blood flow. Signs of anemia, including fatigue, weakness, and pallor. Delayed growth and puberty in children and adolescents. Bone or joint pain caused by bone marrow expansion or infarctions. Sudden neurological symptoms such as weakness, numbness, speech difficulties, or vision problems, indicative of cerebrovascular involvement or strokes. Frequent infections or increased susceptibility to illnesses. Swelling in hands and feet caused by blocked blood flow. Jaundice or yellowing of the skin and eyes due to rapid breakdown of abnormal red blood cells. Signs of organ damage, including liver and spleen enlargement.
Diagnostic & Treatment
Diagnosis Path: Blood tests such as hemoglobin electrophoresis to identify abnormal hemoglobin variants. Complete blood count (CBC) to evaluate anemia severity and red blood cell health. Imaging studies like MRI or CT scans to detect cerebrovascular abnormalities, ischemia, or infarctions. Brain imaging tests to assess for stroke or other cerebrovascular complications. Genetic testing to confirm the specific mutations associated with sickle-cell disease and thalassemia.
Treatment Protocols: Hydroxyurea therapy to reduce sickling episodes and decrease the frequency of pain crises. Regular blood transfusions to treat anemia and prevent stroke, particularly in children at high risk. Iron chelation therapy to manage iron overload from repeated transfusions. Pain management during sickle-cell crises using medications and supportive care. Preventive antibiotics and vaccinations to reduce infection risk. Management of cerebrovascular complications, which may involve medications such as anticoagulants or procedures to restore blood flow. Supportive care including nutritional support, hydration, and lifestyle modifications. Psychological support and counseling to cope with chronic disease management.
Clinical Advice & FAQs
Billing Guidance
Is D57.413 a billable ICD-10 code?
Yes, D57.413 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D57.413?
Clinical documentation must specify the nature of Sickle-cell thalassemia, unspecified, with cerebral vascular involvement and any associated comorbidities for accurate reporting.
Cite this Clinical Reference